Top-News
Chemikalien Frankreich

Ipsen Promesses News

Aktie
WKN:  A0ESMG ISIN:  FR0010259150 US-Symbol:  IPSEF
118,80 €
-1,20 €
-1,00%
16:50:27 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
82,80 Mio.
Marktkapitalisierung *
9,94 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 17.09.2023

Ipsen Promesses News

02.05.24 - GlobeNewswire
Ipsen appoints Keira Driansky as EVP, President of North America
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-​driven biopharmaceutical company, announced today the appointment of Keira Driansky as ...
24.04.24 - GlobeNewswire
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-​care biopharmaceutical company, today presents its sales for the first quarter of 2024.
22.04.24 - GlobeNewswire
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development candidate validation, Ipsen will ...
02.04.24 - GlobeNewswire
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-​drug conjugate, completing the final stages of pre-​clinical development ...
13.02.24 - GlobeNewswire
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  
Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde ® regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically meaningful improvements ...
08.02.24 - GlobeNewswire
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
Total-​sales growth in FY 2023 of 6.7% at CER 1 (3.4% as reported) included strong sales from the growth platforms 2 and good contributions from the new medicines. A core ...
22.01.24 - GlobeNewswire
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
Detailed top-line results from Phase III CONTACT-02 trial demonstrated statistically significant progression-​free survival benefit for combination of Cabometyx ® and atezolizumab in ...
07.12.23 - GlobeNewswire
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
New Drug Application granted priority review with PDUFA date set for June 10, 2024 European Medicines Agency (EMA) has also validated the Marketing Authorization Application ...
07.12.23 - GlobeNewswire
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
PARIS, FRANCE, 7 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-​driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K.
13.11.23 - GlobeNewswire
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
ELATIVE ® Phase III trial confirms potential for investigational elafibranor as a novel, first-​in-class, dual PPAR α,δ agonist for patients with primary biliary cholangitis. Elafibranor ...
26.10.23 - GlobeNewswire
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
Paris (France), 26 October 2023
23.10.23 - GlobeNewswire
Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
Positive opinion from Committee for Medicinal Products for Human Use recommending approval of Bylvay ® (odevixibat) based on Phase III ASSERT clinical-​trial data in Alagille ...
03.10.23 - GlobeNewswire
Ipsen updates on QM-1114 regulatory process
PARIS, FRANCE, 3 October 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its partner Galderma has confirmed receipt from the FDA of a Complete Response Letter ...
04.09.23 - GlobeNewswire
Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
PARIS, FRANCE, 4 September 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-​optation of Pascal Touchon to its Board as an independent director, effective 4 ...
01.09.23 - GlobeNewswire
Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
PARIS, FRANCE, 1 September 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-​driven biopharmaceutical company, announced today the appointment of Christelle ...
21.08.23 - GlobeNewswire
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared with a second novel ...
16.08.23 - GlobeNewswire
US FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-​rare bone disease, fibrodysplasia ossificans progressiva ...
27.07.23 - GlobeNewswire
Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
Paris , France : 27 July 202 3 Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-​care biopharmaceutical company, presents today its financial results for the first half of 2023.
24.07.23 - GlobeNewswire
Ipsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights - effective from December 19, 2023
PARIS, FRANCE, 24 July 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) announced today that the Board of Directors of Ipsen has been informed of certain changes of the shareholders’ ...
21.07.23 - GlobeNewswire
Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome  
Positive opinion from Committee for Medicinal Products for Human Use (CHMP) based on Bylvay Phase III ASSERT clinical-​trial data in Alagille syndrome (ALGS) Negative opinion ...

Newssuche

Videos

07.05.24 -4,91%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »